caa a22 4500 469073780 CHVBK 20180323132929.0 cr unu---uuuuu 170328e19920501xx s 000 0 eng 10.1007/BF01756184 doi (NATIONALLICENCE)springer-10.1007/BF01756184 Glycosidically bound sialic acid levels as a predictive marker of postoperative adjuvant therapy in gastric cancer [Elektronische Daten] [Kyoji Ogoshi, Yasumasa Kondoh, Tomoo Tajima, Toshio Mitomi] Summary: A group of 293 gastric cancer patients were examined to see if the preoperative value of glycosidically bound sialic acid is a predictor of prognosis and effectiveness of postoperative adjuvant therapy. All patients had gastrectomies and were histologically confirmed to have primary adenocarcinoma of the stomach. Some patients then received either postoperative adjuvant chemotherapy or immunochemotherapy. Patients with sialic acid levels less than 74.5 mg/dl survived significantly longer than those with sialic acid levels of 74.5 mg/dl or of 85.3 mg/dl and over. No significant differences in survival were found among patients treated by gastrectomy alone, gastrectomy plus chemotherapy and gastrectomy plus immunochemotherapy. However, patients with abnormally elevated levels of sialic acid survived significantly longer when they were treated with immunochemotherapy after gastrectomy than those treated by gastrectomy alone or with chemotherapy after gastrectomy. By using Cox's multivariate regression model, pTNM stages, postoperative adjuvant therapy (chemotherapy and immunochemotherapy) and preoperative serum levels of sialic acid were examined as prognostic variables. Postoperative therapy was a significant prognostic variable in patients with abnormally elevated levels of sialic acid. The preoperative serum level of sialic acid is a promising predictive marker of the response to postoperative adjuvant immunochemotherapy. Springer-Verlag, 1992 Gastric cancer nationallicence Sialic acid nationallicence Prognosis nationallicence PSK nationallicence Ogoshi Kyoji Department of Surgery, School of Medicine, Tokai University, Bohseidai Isehara, 259-11, Kanagawa, Japan aut Kondoh Yasumasa Department of Surgery, School of Medicine, Tokai University, Bohseidai Isehara, 259-11, Kanagawa, Japan aut Tajima Tomoo Department of Surgery, School of Medicine, Tokai University, Bohseidai Isehara, 259-11, Kanagawa, Japan aut Mitomi Toshio Department of Surgery, School of Medicine, Tokai University, Bohseidai Isehara, 259-11, Kanagawa, Japan aut Cancer Immunology, Immunotherapy Springer-Verlag 35/3(1992-05-01), 175-180 0340-7004 35:3<175 1992 35 262 https://doi.org/10.1007/BF01756184 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01756184 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ogoshi Kyoji Department of Surgery, School of Medicine, Tokai University, Bohseidai Isehara, 259-11, Kanagawa, Japan aut NATIONALLICENCE 700 1- Kondoh Yasumasa Department of Surgery, School of Medicine, Tokai University, Bohseidai Isehara, 259-11, Kanagawa, Japan aut NATIONALLICENCE 700 1- Tajima Tomoo Department of Surgery, School of Medicine, Tokai University, Bohseidai Isehara, 259-11, Kanagawa, Japan aut NATIONALLICENCE 700 1- Mitomi Toshio Department of Surgery, School of Medicine, Tokai University, Bohseidai Isehara, 259-11, Kanagawa, Japan aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 35/3(1992-05-01), 175-180 0340-7004 35:3<175 1992 35 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer